A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study

Ophthalmology

Volumn 127, Issue 3, 2020, Pages 377-393

  Rosenblatt, Amir ^a,b,k   Udaondo, Patricia ^c,k   Cunha Vaz, José ^d,k   Sivaprasad, Sobha ^e,k   Bandello, Francesco ^f,k   Lanzetta, Paolo ^g,h,k   Kodjikian, Laurent ^i,j,k   Goldstein, Michaella ^a,b,k   Habot Wilner, Zohar ^a,b,k   Loewenstein, Anat ^a,b,k   Escobar, Jose Juan ^k   Menon, Geeta ^k   Corcostegui, Borja ^k   Eriksson, Urban ^k   Boixadera, Anna ^k   Sararols, Laura ^k   Guigou, Sebastien ^k   Varano, Monica ^k   Figueira, João ^k   Pollack, Ayalla ^k   Massin, Pascale ^k   Carpineto, Paolo ^k   Recchimurzo, Nicola ^k   Matonti, Frederic ^k   Kinnunen, Kati ^k   Coscas, Florence ^k   Midena, Edoardo ^k   Nascimento, João ^k   Armada, Felix ^k   Sorkin, Nir ^k   more..

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^e MOORFIELDS EYE HOSPITAL   (United Kingdom)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g UNIVERSITY OF UDINE   (Italy)

^h Istituto Europeo di Microchirurgia Oculare   (Italy)

ⁱ CROIX ROUSSE HOSPITAL   (France)

^j UNIVERSITÉ DE LYON   (France)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; HEMOGLOBIN A1C; GLUCOCORTICOID;

AGED; BEST CORRECTED VISUAL ACUITY; CATARACT; CENTRAL MACULAR THICKNESS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC MACULAR EDEMA; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; RETINA DETACHMENT; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT INDICATION; VISUAL ACUITY; VITREOUS HEMORRHAGE; ADULT; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED;

ADULT; AGED; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 85077702571     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2019.10.005     Document Type: Conference Paper

References (37)

1. Frank, R.N., Diabetic retinopathy. N Engl J Med 350:1 (2004), 48–58.
2. Yau, J.W.Y., Rogers, S.L., Kawasaki, R., et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:3 (2012), 556–564.
3. Kobrin Klein, B.E., Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 14:4 (2007), 179–183.
4. International Diabetes Federation. IDF Diabetes Atlas. Vol 8. http://www.diabetesatlas.org/ 2017. Accessed 07.12.15.
5. Scholl, S., Augustin, A., Loewenstein, A., et al. General pathophysiology of macular edema. Eur J Ophthalmol 21:Suppl 6 (2011), S10–S19.
6. Bhagat, N., Grigorian, R.A., Tutela, A., Zarbin, M.A., Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 54:1 (2009), 1–32.
7. Wells, J.A., Glassman, A.R., Ayala, A.R., et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123:6 (2016), 1351–1359.
8. Gonzalez, V.H., Campbell, J., Holekamp, N.M., et al. Early and long-term responses to anti–vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol 172 (2016), 72–79.
9. Dugel, P.U., Campbell, J.H., Kiss, S., et al. Association between early anatomic response to anti–vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema. Retina 39:1 (2019), 88–97.
10. Busch, C., Zur, D., Fraser-Bell, S., et al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol 55:8 (2018), 789–796.
11. Boyle, J., Vukicevic, M., Koklanis, K., et al. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med 23:2 (2018), 127–140.
12. Bressler, S.B., Glassman, A.R., Almukhtar, T., et al. Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema. Am J Ophthalmol 164 (2016), 57–68.
13. Funatsu, H., Noma, H., Mimura, T., et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116:1 (2009), 73–79.
14. Allergan, Inc. Highlights of prescribing information. https://www.allergan.com/assets/pdf/ozurdex_pi.pdf 2018. Accessed 20.05.18.
15. Chang-Lin, J.-E., Attar, M., Acheampong, A.A., et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Opthalmol Vis Sci 52:1 (2011), 80–86.
16. Boyer, D.S., Yoon, Y.H., Belfort, R., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:10 (2014), 1904–1914.
17. Querques, G., Darvizeh, F., Querques, L., et al. Assessment of the real-life usage of intravitreal dexamethasone implant in the treatment of chronic diabetic macular edema in France. J Ocul Pharmacol Ther 32:6 (2016), 383–389.
18. Aknin, I., Melki, L., Longitudinal study of sustained-release dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmologica 235:4 (2016), 187–188.
19. Dutra Medeiros, M., Postorino, M., Navarro, R., et al. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica 231:3 (2014), 141–146.
20. Scaramuzzi, M., Querques, G., Spina, C.L., et al. Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. Retina 35:6 (2015), 1216–1222.
21. Matonti, F., Pommier, S., Meyer, F., et al. Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. Eur J Ophthalmol 26:5 (2016), 454–459.
22. Chhablani, J., Bansal, P., Veritti, D., et al. Dexamethasone implant in diabetic macular edema in real-life situations. Eye 30:3 (2016), 426–430.
23. Malclès, A., Dot, C., Voirin, N., et al. Real-life study in diabetic macular edema treated with dexamethasone implant. Retina 37:4 (2017), 753–760.
24. Singer, M.A., Dugel, P.U., Fine, H.F.A.C. Jr., Maltman, J., Real-world assessment of dexamethasone intravitreal implant in DME: findings of the prospective, multicenter REINFORCE Study. Ophthalmic Surg Lasers Imaging Retin 49:6 (2018), 425–436.
25. Sivaprasad, S., Oyetunde, S., Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol 10 (2016), 939–946.
26. Malclès, A., Dot, C., Voirin, N., et al. Real-life study in diabetic macular edema treated with dexamethasone implant: the Reldex Study. Retina 37:4 (2017), 753–760.
27. Chatziralli, I., Theodossiadis, P., Parikakis, E., et al. Dexamethasone intravitreal implant in diabetic macular edema: real-life data from a prospective study and predictive factors for visual outcome. Diabetes Ther 8 (2017), 1393–1404.
28. Iglicki, M., Busch, C., Zur, D., et al. Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: the International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study. Retina 39:1 (2019), 44–51.
29. Callanan, D.G., Gupta, S., Boyer, D.S., et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 120 (2013), 1843–1851.
30. Guigou, S., Hajjar, C., Parrat, E., et al. Multicenter Ozurdex® assessment for diabetic macular edema: MOZART study [in French]. J Fr Ophtalmol 37:6 (2014), 480–485.
31. Esen, E., Sizmaz, S., Demircan, N., Efficacy of dexamethasone intravitreal implant for the treatment of persistent diffuse diabetic macular edema. Int Ophthalmol 37:1 (2017), 1–6.
32. Guigou, S., Pommier, S., Meyer, F., et al. Efficacy and safety of intravitreal dexamethasone implant in patients with diabetic macular edema. Ophthalmologica 233:3–4 (2015), 169–175.
33. Augustin, A.J., Kuppermann, B.D., Lanzetta, P., et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol, 15, 2015, 150.
34. Escobar-Barranco, J.J., Pina-Marín, B., Fernández-Bonet, M., Dexamethasone implants in patients with naïve or refractory diffuse diabetic macular edema. Ophthalmologica 233:3–4 (2015), 176–185.
35. Cunha-Vaz, J., Ashton, P., Iezzi, R., et al. Sustained delivery fluocinolone acetonide vitreous implants. Ophthalmology, 121(10), 2014 1892–1903.e3.
36. Diabetes Control and Complications Trial Research Group, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:14 (1993), 977–986.
37. ACCORD Study Group, ACCORD Eye Study Group, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363:3 (2010), 233–244.